Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Eur Ann Allergy Clin Immunol ; 50(3): 135-138, 2018 05.
Article in English | MEDLINE | ID: mdl-29479928

ABSTRACT

Summary: Background. Microarray technique employing molecular allergens is pointed out as a new method to evaluate allergic patients. Objective. To evaluate if microarray technique (ImmunoCAP-ISAC®; I-ISAC®) is similar to fluorescence enzyme immunoassay (FEIA; ImmunoCAP®) in the diagnosis of latex allergy (specific IgE to latex plus symptoms) and latex sensitization (only antibody) in pediatric (9-mo to 14-yrs) patients with myelomeningocele undergone to surgical repair. Methods. Patients underwent skin prick testing (SPT) to latex and food (prick to prick), and dosage of serum specific IgE to latex and recombinant latex allergens (rHev b 1, rHev b 3, rHev b 5, rHev b 6.01, rHev b 6.02, rHev b 8, rHev b 9, and rHev b 11) by ImmunoCAP® and I-ISAC®. Results. The comparison between the two methods showed high level of concordance considering positive and negative results. A statistically significant correlation for rHev b 3 and rHev b 6.01 for the allergic patients, and for rHev b5 and rHev b6.01 for those sensitized to latex, was observed. I-ISAC® is limited to 5 recombinant latex allergens (rHev b 1, 3, 5, 6.01 and 8). Despite the presence of antibodies against pollens, LTP and profilins (I-ISAC®) in some patients, none of them reported symptoms related with intake of fruits and/or vegetables. Conclusion. Both methods are effective in assisting the diagnosis of latex allergy, but differ in the assessment of sensitized pediatric patients with myelomeningocele. The assessment of latex sensitized patients is more complete using the 8 recombinant latex fractions available for ImmunoCAP®, instead of I-ISAC®.


Subject(s)
Fluoroimmunoassay/methods , Latex Hypersensitivity/diagnosis , Meningomyelocele/surgery , Protein Array Analysis/methods , Adolescent , Child , Child, Preschool , Food Hypersensitivity/diagnosis , Humans , Immunoglobulin E/blood , Infant , Latex/immunology , Meningomyelocele/pathology
9.
Clin Ter ; 157(6): 511-5, 2006.
Article in English | MEDLINE | ID: mdl-17228850

ABSTRACT

OBJECTIVE: The aim of this nonrandomized observational study is to verify and confirm whether it is possible to use insulin glargine (Lantus) subcutaneously in patients receiving parenteral nutrition (PN) and whether the analogue is capable of obtaining and maintaining good glycemic control without inducing hypoglycemia. MATERIALS AND METHODS: The sample is made up of 25 patients with severe hepato-gastroenterology diseases receiving parenteral nutrition, diagnosed diabetics and non-diabetics, who had previously been prescribed traditional insulin therapy. All were to be given subcutaneous insulin glargine at a dosage equal to the average of insulin/day administered in the preceding days spent receiving PN. RESULTS: Twenty-five consecutive patients, not stratified in any way, were judged eligible in the last six months of 2004 and first eight months of 2005. Four out of these 25 cannot be evaluated, either because (2/4) they did not begin or complete the treatment with Lantus or because the proper number of glycemic tests were not done (2/4); 21/25 patients, 84% of the sample with a mean age of 65.9 years (range 46-93 yr), finished the study and can be evaluated. The mean glycemic values after treatment with glargine were already better on the second day, and on the seventh day the difference was statistically significant. No hypoglycemias occurred which required medical intervention. CONCLUSIONS: This study confirms the possibility of using insulin glargine in patients receiving parenteral nutrition with hyperglycemia diagnosed diabetics or not diabetics.


Subject(s)
Hyperglycemia/drug therapy , Hypoglycemic Agents/therapeutic use , Insulin/analogs & derivatives , Parenteral Nutrition , Aged , Aged, 80 and over , Blood Glucose/analysis , Data Interpretation, Statistical , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Gastrointestinal Diseases/complications , Humans , Hyperglycemia/blood , Hyperglycemia/diagnosis , Hypoglycemic Agents/administration & dosage , Injections, Subcutaneous , Insulin/administration & dosage , Insulin/therapeutic use , Insulin Glargine , Insulin, Long-Acting , Liver Diseases/complications , Middle Aged
10.
Boll Soc Ital Biol Sper ; 54(22): 2319-25, 1978 Nov 30.
Article in Italian | MEDLINE | ID: mdl-224892

ABSTRACT

Male and female rats were treated with estradiol benzoate in the 5 degrees day of life. The avoidance conditioning, tested after 65 days, was significatively impaired in males treated with estradiol, a significative retardation was observed in females treated, but no significant end-difference versus no-treated females. It is supposed that a hormone induced synaptic shaft/spines ratio in preoptic area may be involved in avoidance conditioning.


Subject(s)
Avoidance Learning/drug effects , Estradiol/pharmacology , Amygdala/drug effects , Animals , Female , Gonadotropins/metabolism , Male , Preoptic Area/drug effects , Rats , Receptors, Neurotransmitter/drug effects , Sex Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...